Financial Data and Key Metrics Changes - In Q4 2025, worldwide sales reached $24.6 billion, a 7.1% increase despite a 650 basis point headwind from Stelara [20][21] - For the full year 2025, worldwide sales totaled $94.2 billion, reflecting a 5.3% increase, with U.S. growth at 6.9% and 3.4% outside the U.S. [21][22] - Net earnings for Q4 were $5.1 billion, with diluted earnings per share at $2.10, compared to $1.41 a year ago [21] - Full year 2025 adjusted net earnings were $26.2 billion, with adjusted diluted earnings per share at $10.79, an 8.1% increase from 2024 [23][31] Business Line Data and Key Metrics Changes - Innovative Medicine reported Q4 sales of $15.8 billion, a 7.9% increase, with significant contributions from oncology and immunology [24] - In oncology, Darzalex grew 24.1%, while Carvykti achieved sales of $555 million with 63.2% growth [24][25] - Tremfya in immunology saw remarkable growth of 65.4%, with full year sales exceeding $5 billion for the first time [14][25] - MedTech sales reached $8.8 billion in Q4, a 5.8% increase, driven by strong performance in cardiovascular and surgical segments [26][27] Market Data and Key Metrics Changes - In oncology, operational sales grew 21% in 2025, with expectations to exceed $50 billion in annual sales by 2030 [10] - The cardiovascular segment delivered 15% operational sales growth, with Abiomed and Shockwave showing strong performance [16][26] - Vision care saw robust growth, particularly in Surgical Vision, with a 10.8% increase driven by new product innovations [27] Company Strategy and Development Direction - The company plans to separate its Orthopaedics business to focus on high-growth areas [7] - Investments of over $32 billion in R&D and M&A in 2025, including acquisitions of Intra-Cellular Therapies and Halda Therapeutics, are aimed at accelerating growth [8] - The company aims for double-digit growth by the end of the decade, supported by a diverse portfolio of 28 products generating over $1 billion annually [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving faster growth in 2026 compared to 2025, driven by a strong pipeline and portfolio [8][19] - The company anticipates operational sales growth of 5.7%-6.7% for 2026, with a midpoint of $100 billion [35] - Management highlighted the importance of innovation in driving future growth and improving patient outcomes [43][55] Other Important Information - The company ended 2025 with approximately $20 billion in cash and marketable securities, generating $19.7 billion in free cash flow [34] - The effective tax rate for Q4 2025 was a benefit of 3%, compared to an 11.7% cost in Q4 2024 [30] Q&A Session Summary Question: Overview of growth potential and strategic repositioning - Analyst inquired about the key levers for achieving double-digit growth and the impact of the strategic repositioning away from lower growth segments [47] - Management responded that the strength of the portfolio and pipeline, particularly in oncology and immunology, supports the growth outlook [48][49] Question: MedTech market dynamics and growth expectations - Analyst asked about the MedTech market outlook for 2026 and the expected growth acceleration [58] - Management indicated confidence in growth despite potential policy changes, emphasizing strong clinical demand and strategic focus on higher growth markets [59][60] Question: Margin progression and relationship to top-line growth - Analyst sought clarification on margin progression in relation to expected top-line growth [68] - Management explained that margin improvements are expected to align with sales growth, particularly following the orthopedic separation [70][71] Question: Vision Care market health and performance - Analyst requested insights on the Vision Care market and performance discrepancies between regions [73] - Management highlighted strong underlying performance in the contact lens category and ongoing focus on vision as a growth area [74]

Financial Data and Key Metrics Changes - The overall growth in the first quarter was 4.1%, with the pharmaceutical group growing by 4.2% and the med tech group by 4% [10] - The company has delivered consistent results, meeting or exceeding analyst expectations in earnings for 28 consecutive quarters over the past seven years [9] - The company has committed to a growth target of 5% to 7% from 2025 to 2030, with confidence in achieving this based on current results [11] Business Line Data and Key Metrics Changes - The pharmaceutical group showed a growth of 4.2% despite facing headwinds from biosimilars for its major product, Stellara [10] - The med tech group also reported a growth of 4%, indicating stability across both segments [10] - The company has invested $50 billion in M&A and R&D over the last two years, with an additional $55 billion planned for R&D manufacturing and technology in the U.S. over the next four years [11] Market Data and Key Metrics Changes - The company is optimistic about the biopharmaceutical and medical technology industries, citing significant medical innovation opportunities [5][22] - The U.S. market is seen as a key area for growth, with the administration's support for American businesses and manufacturing jobs [6] Company Strategy and Development Direction - Johnson & Johnson emphasizes its unique position as a healthcare company that spans the entire patient journey, with unmatched breadth in capabilities [7] - The company is focused on maintaining leadership in cardiac ablation and investing in new technologies to enhance its med tech offerings [56] - The strategy includes moving into higher growth markets, particularly in cardiovascular and robotics [85] Management's Comments on Operating Environment and Future Outlook - Management remains optimistic about the industry despite macro uncertainties, highlighting a combination of headwinds and tailwinds [5][22] - The company is actively engaging with the administration to ensure continued innovation while making medicines affordable [23] - Management believes there are significant disconnects between market expectations and the company's potential, particularly in new product launches [12][14] Other Important Information - The company has a strong track record of dividend increases for 63 consecutive years, reflecting its financial stability [9] - The company is committed to improving gross margins and has various efficiency programs in place [51][54] Q&A Session Summary Question: How does the company view the current macro environment and its impact? - Management expressed optimism about the biopharmaceutical and medical technology industries, noting the potential for innovation despite uncertainties [22] Question: What is the company's strategy regarding drug pricing reforms? - Management highlighted the need for dialogue with the administration to balance innovation and affordability in medicines [24][30] Question: Can you provide an update on the talc litigation? - The company is back in the tort system and is confident in its position, having won 16 out of 17 cases related to ovarian cancer [37][38] Question: What are the expectations for financial performance in 2025? - The company is guiding for organic sales growth of 2% to 3% and EPS growth of 5% to 7%, with optimism about pharmaceutical product performance [43] Question: How does the company plan to address competitive pressures in the med tech space? - Management emphasized a commitment to innovation in cardiac ablation and plans to enhance its product offerings in electrophysiology [56][65]